SCHEDULE Filed 2025-01-31 Event 2025-01-31 SEC 0000950170-25-011961 →

PERCEPTIVE ADVISORS LLC → Nautilus Biotechnology, Inc. NAUT

Stake: 10.00% Shares: 12,594,211 CUSIP: 63909J108 Class: Common Stock, par value $0.0001 per share

Item 4 — Purpose of Transaction

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On January 28, 2025, Michael Altman, a Managing Director of Perceptive Advisors who has served on the Issuer's board of directors (the "Board") since June 2021, informed the Issuer that he will not stand for reelection to the Board at the Issuer's 2025 Annual Meeting of Stockholders (the "Annual Meeting"). Mr. Altman will remain a member of the Board until the conclusion of the Annual Meeting.

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

1 13D/G filings on this issuer

0 other filings besides this one

Filer Track Record

7 filings by this filer

6 other filings in the data moat

Short Interest · settle 2026-03-31

DTC 1.34

674,952 shares short · +51.1% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $119K

Point72 Asset Mgmt

Other Filings by PERCEPTIVE ADVISORS LLC

Filed	Form	Issuer	Stake	Shares
2026-01-26	SCHEDULE	TRINITY BIOTECH PLC TRIB	9.90%	1,463,058,248	view →
2026-01-02	SCHEDULE	MeiraGTx Holdings plc MGTX	12.90%	10,441,562	view →
2025-02-21	SCHEDULE	Solid Biosciences Inc. SLDB	15.60%	11,934,679	view →
2025-02-14	SCHEDULE	TRINITY BIOTECH PLC TRIB	20.90%	85,800,000	view →
2022-07-01	SC	Athira Pharma, Inc. LONA	—	—	view →
2021-04-06	SC	Landos Biopharma, Inc.	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →